Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ThromboGenics has signed an agreement with Alcon, a division of Novartis, for the commercialization of ocriplasmin in all markets outside the US.
Subscribe to our email newsletter
Under the agreement, ThromboGenics will receive an upfront payment of €75m, is also entitled to a further €90m in potential near-term milestone payments.
In addition, ThromboGenics will receive royalties on net sales of ocriplasmin that are proportionate with a product.
ThromboGenics will have a strategic and focused operational role in the commercialization of ocriplasmin in the five largest European markets, according to the deal.
The completed Phase III studies showed that ocriplasmin could play an important role in treating symptomatic vitreomacular adhesion (VMA) including macular hole.
Alcon and ThromboGenics will also work together, and share the costs, to further develop new clinical applications of ocriplasmin.